Replimune Group (NASDAQ:REPL) Shares Up 5.3% – Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price shot up 5.3% during trading on Friday . The company traded as high as $10.09 and last traded at $10.0230. Approximately 1,265,025 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 4,505,842 shares. The stock had previously closed at $9.52.

Analyst Upgrades and Downgrades

Several research firms have issued reports on REPL. Jefferies Financial Group restated a “hold” rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Weiss Ratings downgraded Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 2nd. Wedbush boosted their target price on Replimune Group from $6.00 to $9.00 and gave the company a “neutral” rating in a research note on Tuesday, June 30th. Finally, BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.12.

Replimune Group Stock Up 7.5%

The stock’s fifty day moving average is $8.68 and its 200 day moving average is $7.39. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $858.71 million, a P/E ratio of -3.03 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Research analysts predict that Replimune Group, Inc. will post -2.54 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently bought and sold shares of REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Replimune Group by 17.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after buying an additional 6,653 shares during the period. Millennium Management LLC raised its holdings in shares of Replimune Group by 2.8% during the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after acquiring an additional 119,145 shares during the period. Rhumbline Advisers lifted its stake in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after acquiring an additional 6,616 shares during the period. Finally, Sei Investments Co. boosted its holdings in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after acquiring an additional 18,263 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.